-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78

Benzinga·11/05/2026 21:50:40
Listen to the news
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $70 to $78.